Apellis Pharmaceuticals Inc
25 articles with Apellis Pharmaceuticals Inc
-
The JP Morgan Healthcare Conference is wrapping up today and as usual, it’s host to some of the biggest names in biopharma, but it’s also a venue where tiny biotechs and even mid-size biopharma companies go to meet-and-greet with others in the industry.
-
Enable Injections Enters into Strategic Partnerships with UCB and Apellis Pharmaceuticals
11/13/2018
Patient-centric drug delivery important for treatment adherence, commercial success
-
Apellis Pharmaceuticals Reports Second Quarter 2018 Business Update and Financial Results
7/31/2018
Commenced Phase 3 Trial of APL-2 in Paroxysmal Nocturnal Hemoglobinuria (PNH); APL-2 in Geographic Atrophy (GA) Remains On Track to Advance into Phase 3 in 2H18
-
Apellis Pharmaceuticals Announces First Patient Enrolled in Phase 3 APL-2 Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Soliris™
6/26/2018
Apellis Pharmaceuticals Inc. announced that it has commenced its PEGASUS Phase 3 trial assessing the safety and efficacy of APL-2 in patients with paroxysmal nocturnal hemoglobinuria (PNH) compared to eculizumab (Soliris™).
-
Apellis Pharmaceuticals to Host R&D Day on June 26, 2018
6/19/2018
Apellis Pharmaceuticals, Inc. announced that it will host an R&D Day from 2:00 p.m. to 5:00 p.m. Eastern Time on June 26, 2018 in New York City.
-
Apellis Finalizes Phase III Clinical Trial Plans for Geographic Atrophy Treatment With APL-2
12/21/2017
The Phase 3 program, planned to begin in the second half of 2018, will consist of two identical 600-patient prospective, multicenter, randomized, double-masked, sham-injection controlled studies to assess the efficacy and safety of multiple intravitreal injections of APL-2 in patients with GA.
-
Apellis Pharma Expands Management Team, Appoints Timothy Sullivan CFO
12/19/2017
Prior to joining as CFO, Sullivan was an observer on Apellis' board of directors for nearly three years while he was a Partner at AJU IB Investment, a venture capital firm, where he led the firm's investments in life sciences companies.
-
Epidarex Capital Portfolio Company Apellis Pharmaceuticals Completes IPO
11/14/2017
Epidarex and its predecessor fund, MASA Life Science Ventures, were among the company's earliest backers, funding the development of the company's core technology shortly after its spin-out from the University of Pennsylvania.
-
Apellis Pharmaceuticals Announces Closing of its Initial Public Offering
11/14/2017
The total gross proceeds to Apellis were approximately $150.0 million, before deducting underwriting discounts and commissions and expenses payable by Apellis.
-
The Crestwood, KY-based company plans to raise $150M by offering 10.7 million shares at a price range of $13 to $15.
-
Apellis Pharma's Eye Drug Meets Primary Endpoint in Mid-Stage Study
8/24/2017
-
Apellis Pharma Nabs $60 Million to Advance APL-2 into Phase III Trials
8/10/2017
-
Apellis Pharma Announces $60 Million Series E Financing
8/10/2017
-
Apellis Pharma Release: Positive Data From APL-2 Studies Show Rapid And Durable Improvements In LDH And Hemoglobin Levels
6/29/2017
-
Apellis Pharma Receives EMA Orphan Drug Designation For APL-2 In PNH
5/9/2017
-
Apellis Pharma Announces FDA Fast Track Designation For APL-2 In PNH
12/20/2016
-
Apellis Pharma Reports Positive Interim Results From Phase Ib Clinical Trials Of APL-2 In PNH
12/2/2016
-
Apellis Pharma To Present Safety And Efficacy Data From Clinical Trials Of APL-2 In PNH At December Scientific Meetings
11/21/2016
-
Apellis Pharma Announces Appointment Of Dr. Robert Kim As Chief Medical Officer
8/8/2016
-
Apellis Pharma Announces Positive Results From Phase 1 Clinical Trials Of APL-2, A C3 Complement Inhibitor
6/23/2016